Atezolizumab and Bevacizumab With Photon Radiotherapy for Unresectable Hepatocellular Carcinoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Atezolizumab (anti-programmed death-ligand 1; anti-PD-L1) in conjunction with bevacizumab (anti-vascular endothelial growth factor; anti-VEGF) has become the established standard first-line systemic treatment for unresectable hepatocellular carcinoma (HCC). Despite an improved objective response rate (ORR) of 27%, the majority of patients face HCC progression and liver failure \[Finn et al., N Engl J Med 2020\]. Developing a new combined treatment strategy to overcome resistance to anti-PD-L1 and anti-VEGF is essential to improve patient outcomes. Radiation treatment (RT) is highly efficacious in controlling localized solid tumors and has become an integral component of the treatment algorithm for unresectable HCC. Importantly, a recent retrospective cohort described that RT combined with atezolizumab plus bevacizumab was associated with favorable median overall survival of 16.1 months (Manzar et al, Cancers 2022). Our preclinical study (Hsieh et al., Science Immunology 2022) revealed that RT combined with PD-L1/PD-1 blockade induces immunogenic cell death and tumor antigen cross-presentation in antigen-presenting cells, thereby potentiating the systemic antitumor T cell responses in murine tumor models. However, whether the combinatorial therapy with RT, atezolizumab, and bevacizumab can trigger synergistic antitumor effects and systemic immune mobilization has not yet been validated in clinical trials for unresectable HCC. Both atezolizumab/bevacizumab and X-ray RT are approved treatment methods for unresectable HCC by the U.S. and Taiwan Food and Drug Administration (FDA). The present phase II non-randomized trial aims to prospectively document the therapeutic efficacy, safety, and immunological responses in patients with unresectable HCC treated with atezolizumab/bevacizumab combined with conventional photon radiotherapy.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Diagnoza raka wątroby, która nie pozwala na operację ani przeszczep.
- •Wiek 18 lat lub więcej.
- •Stan ogólny pacjenta pozwala na podstawowe czynności życiowe (skala 0-1).
- •Rak wątroby w stadium pośrednim lub zaawansowanym.
- •Dobra czynność wątroby.
- •Posiadanie wyników badań potwierdzających brak lub obecność wirusowego zapalenia wątroby typu B i C.
- •Zrozumienie i chęć podpisania zgody na udział w badaniu.
- •Odpowiednia ilość komórek krwi, prawidłowe wyniki prób wątrobowych, nerkowych i krzepnięcia.
✗ Disqualifies
- •Przebyty inny nowotwór, który nie był leczony dłużej niż 2 lata temu.
- •Wcześniejsze leczenie radioterapią w okolicy wątroby, które kolidowałoby z obecnym leczeniem.
- •Wcześniejsze specjalistyczne leczenie wątroby (np. SIRT/TACE).
- •Aktywne, nieleczone zapalenie wątroby typu B lub C.
- •Duża ilość płynu w jamie brzusznej (wodobrzusze).
- •Przerzuty w miejscach, które nie mogą być objęte leczeniem radioterapią.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 1, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Chang Gung Memorial Hospital at Linkou
Taoyuan City, Taiwan
Trial contact
Rodney Cheng-En Hsieh, MD, PhD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/2/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.